Cargando…

An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease

The ability of clopidogrel (Plavix) to work in tandem with aspirin in a dual therapy strategy to boost the anti-platelet therapeutic impact and diminish platelet aggregation induced by platelet receptor inhibition is one of its many key advantages. The researchers discovered that the average reducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Iskandar, Nicholas P, Reddy, Akshay J, Dang, Allen, Ghauri, Muhammad S, Min, Mildred, Bachir, Mark, Bachir, Alex, Wagh, Himanshu, Tak, Nathaniel, Brahmbhatt, Hetal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509004/
https://www.ncbi.nlm.nih.gov/pubmed/36171852
http://dx.doi.org/10.7759/cureus.28406
_version_ 1784797140424327168
author Iskandar, Nicholas P
Reddy, Akshay J
Dang, Allen
Ghauri, Muhammad S
Min, Mildred
Bachir, Mark
Bachir, Alex
Wagh, Himanshu
Tak, Nathaniel
Brahmbhatt, Hetal
author_facet Iskandar, Nicholas P
Reddy, Akshay J
Dang, Allen
Ghauri, Muhammad S
Min, Mildred
Bachir, Mark
Bachir, Alex
Wagh, Himanshu
Tak, Nathaniel
Brahmbhatt, Hetal
author_sort Iskandar, Nicholas P
collection PubMed
description The ability of clopidogrel (Plavix) to work in tandem with aspirin in a dual therapy strategy to boost the anti-platelet therapeutic impact and diminish platelet aggregation induced by platelet receptor inhibition is one of its many key advantages. The researchers discovered that the average reduction in risk of adverse cardiovascular events related to Plavix much outweighed any potential systemic effects. The analysis also revealed that, even though treatment results for diabetic patients with coronary microvascular disease (CMD) are poorer, the dosage and administration of clopidogrel for dual therapy are not modified to address this issue. Although it has been established that the current standard of care for microvascular disease decreases damage, more study is necessary to ensure that this standard is enhanced. It may become more usual in the future to include patient groups in trials who do not have diabetes as a criterion. Patients with diabetes often have higher low-density lipoprotein (LDL) cholesterol levels than the general population, therefore, it is possible that the research findings are flawed. To confirm or reject this assumption, further research is necessary.
format Online
Article
Text
id pubmed-9509004
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-95090042022-09-27 An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease Iskandar, Nicholas P Reddy, Akshay J Dang, Allen Ghauri, Muhammad S Min, Mildred Bachir, Mark Bachir, Alex Wagh, Himanshu Tak, Nathaniel Brahmbhatt, Hetal Cureus Cardiology The ability of clopidogrel (Plavix) to work in tandem with aspirin in a dual therapy strategy to boost the anti-platelet therapeutic impact and diminish platelet aggregation induced by platelet receptor inhibition is one of its many key advantages. The researchers discovered that the average reduction in risk of adverse cardiovascular events related to Plavix much outweighed any potential systemic effects. The analysis also revealed that, even though treatment results for diabetic patients with coronary microvascular disease (CMD) are poorer, the dosage and administration of clopidogrel for dual therapy are not modified to address this issue. Although it has been established that the current standard of care for microvascular disease decreases damage, more study is necessary to ensure that this standard is enhanced. It may become more usual in the future to include patient groups in trials who do not have diabetes as a criterion. Patients with diabetes often have higher low-density lipoprotein (LDL) cholesterol levels than the general population, therefore, it is possible that the research findings are flawed. To confirm or reject this assumption, further research is necessary. Cureus 2022-08-25 /pmc/articles/PMC9509004/ /pubmed/36171852 http://dx.doi.org/10.7759/cureus.28406 Text en Copyright © 2022, Iskandar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Iskandar, Nicholas P
Reddy, Akshay J
Dang, Allen
Ghauri, Muhammad S
Min, Mildred
Bachir, Mark
Bachir, Alex
Wagh, Himanshu
Tak, Nathaniel
Brahmbhatt, Hetal
An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
title An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
title_full An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
title_fullStr An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
title_full_unstemmed An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
title_short An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
title_sort examination of clopidogrel in the treatment of coronary microvascular disease
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509004/
https://www.ncbi.nlm.nih.gov/pubmed/36171852
http://dx.doi.org/10.7759/cureus.28406
work_keys_str_mv AT iskandarnicholasp anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT reddyakshayj anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT dangallen anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT ghaurimuhammads anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT minmildred anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT bachirmark anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT bachiralex anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT waghhimanshu anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT taknathaniel anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT brahmbhatthetal anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT iskandarnicholasp examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT reddyakshayj examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT dangallen examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT ghaurimuhammads examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT minmildred examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT bachirmark examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT bachiralex examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT waghhimanshu examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT taknathaniel examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease
AT brahmbhatthetal examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease